research use only

RMC-6291 (Elironrasib) KRAS G12C Inhibitor

Name: RMC-6291 (Elironrasib)
Brand: Selleck Chemicals
SKU: E1606
Availability: InStock
Rating: 5 (1 reviews)

Cat.No.E1606

RMC-6291 is an orally active and covalent inhibitor of KRAS^G12C(ON). RMC-6291 forms a tri-complex within tumor cells between KRASG12C(ON) and cyclophilin A (CypA).

RMC-6291 (Elironrasib) KRas inhibitor Chemical Structure

Quality Control

Batch: E160601 DMSO]100 mg/mL]false]Ethanol]100 mg/mL]false]Water]Insoluble]false Purity: 99.03%

Cited in Nature Medicine for its top-tier quality
COA
HPLC
SDS/MSDS
Datasheet

99.03

Related Targets	CXCR Hedgehog/Smoothened PKA Adrenergic Receptor AChR 5-HT Receptor Histamine Receptor Dopamine Receptor Ras GPR
Other KRas Inhibitors	RMC-7977 Daraxonrasib (RMC-6236) MRTX1133 Zoldonrasib (RMC-9805) BI-2852 Adagrasib (MRTX849) HRS-4642 ARS-1620 BI-3406 ARS-853

Solubility

In vitro
Batch:

DMSO : 100 mg/mL (98.78 mM)
(Moisture-contaminated DMSO may reduce solubility. Use fresh, anhydrous DMSO.)

Ethanol : 100 mg/mL

Water : Insoluble

Molarity Calculator

Mass	Concentration	Volume	Molecular Weight
Mass value Mass unit	Concentration value Concentration unit	Volume value Volume unit	Molecular weight (g/mol)

Dilution Calculator Molecular Weight Calculator

In vivo batch selection In vivo Batch:
Homogeneous suspension	CMC-NA	≥5mg/ml	Taking the 1 mL working solution as an example, add 5 mg of this product to 1 ml of CMC-Na solution, mix evenly to obtain a homogeneous suspension with a final concentration of 5 mg/ml.
Clear solution	5%DMSO 1 40%PEG300 2 5%Tween80 3 50%ddH2O Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	5.000mg/ml (4.94mM)	Taking the 1 mL working solution as an example, add 50 μL of 100 mg/ml clarified DMSO stock solution to 400 μL PEG300, mix evenly to clarify it; add 50 μL Tween80 to the above system, mix evenly to clarify it; then continue to add 500 μL ddH2O to adjust the volume to 1 mL. The mixed solution should be used immediately for optimal results.
Clear solution	5% DMSO 1 95% corn oil Validated by Selleck labs. Should you need adjustments to this formulation, contact our sales team for custom testing.	1.650mg/ml (1.63mM)	Taking the 1 mL working solution as an example, add 50 μL of 33 mg/ml clear DMSO stock solution to 950 μL of corn oil and mix evenly. The mixed solution should be used immediately for optimal results.

In vivo Formulation Calculator (Clear solution)

Step 1: Enter information below (Recommended: An additional animal making an allowance for loss during the experiment)

Dosage: mg/kg

Average weight of animals: g

Dosing volume per animal: μL

Number of animals:

Step 2: Enter the in vivo formulation (This is only the calculator, not formulation. Please contact us first if there is no in vivo formulation at the solubility Section.)

% DMSO

% Tween 80

% ddH₂O

% DMSO

Calculation results:

Working concentration: mg/ml;

Method for preparing DMSO master liquid: mg drug pre-dissolved in μL DMSO ( Master liquid concentration mg/mL, Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug. )

Method for preparing in vivo formulation: Take μL DMSO master liquid, next addμL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH₂O, mix and clarify.

Method for preparing in vivo formulation: Take μL DMSO master liquid, next add μL Corn oil, mix and clarify.

Note: 1. Please make sure the liquid is clear before adding the next solvent.
2. Be sure to add the solvent(s) in order. You must ensure that the solution obtained, in the previous addition, is a clear solution before proceeding to add the next solvent. Physical methods such
as vortex, ultrasound or hot water bath can be used to aid dissolving.

Chemical Information, Storage & Stability

Molecular Weight	1012.26	Formula	C₅₅H₇₈FN₉O₈	Storage (From the date of receipt)	3 years-20°Cpowder
CAS No.	2641998-63-0	Download SDF		Storage of Stock Solutions	1 year-80°Cin solvent 1 month-20°Cin solvent

Read more about storage stability stock solution CAS number

Mechanism of Action

Targets/IC₅₀/Ki	KRAS-G12C(ON)
References	[1] https://aacrjournals.org/cancerres/article/82/12_Supplement/3595/702322

Clinical Trial Information

(data from https://clinicaltrials.gov, updated on 2026-06-30)

NCT Number	Recruitment	Conditions	Sponsor/Collaborators	Start Date	Phases
NCT06162221	RECRUITING	Non-Small Cell Lung Cancer, NSCLC; KRAS, NRAS, HRAS-mutated NSCLC; KRAS G12C-mutated Solid Tumors, Lung Cancer; Lung Cancer Stage IV, Advanced Solid Tumor, Cancer; RAS G12D-mutated NSCLC	Revolution Medicines, Inc.	2024-01-18	PHASE1; PHASE2
NCT05462717	ACTIVE_NOT_RECRUITING	Non-Small Cell Lung Cancer (NSCLC); Colorectal Cancer (CRC); Pancreatic Ductal Adenocarcinoma; Advanced Solid Tumor	Revolution Medicines, Inc.	2022-09-19	PHASE1
NCT06128551	Recruiting	Non-Small Cell Lung Cancer (NSCLC)\|Colorectal Cancer\|Pancreatic Ductal Adenocarcinoma	Revolution Medicines Inc.	2023-11-14	Phase 1
NCT05462717	Recruiting	Non-Small Cell Lung Cancer (NSCLC)\|Colorectal Cancer (CRC)\|Pancreatic Ductal Adenocarcinoma\|Advanced Solid Tumor	Revolution Medicines Inc.	2022-09-19	Phase 1

Tech Support

Handling Instructions

Tel: +1-832-582-8158 Ext:3

If you have any other enquiries, please leave a message.

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):